Arcturus Therapeutics Expands Operations Campus In San Diego, California
11/04/2014
Founded in 2013, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. Arcturus has developed a novel, potent and safe RNA Therapeutics platform called LUNAR, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, antisense, and microRNA oligotherapeutics. The company owns Unlocked Nucleic Acid chemistry technology and patent portfolio enabling the targeting of any gene in the human genome.
"The Arcturus story began at the cutting edge Johnson and Johnson Innovation Center here in San Diego. Today, we are 'graduating' from the incubator space and moving into top-tier facilities that will enable us to execute our vision of bringing transformational life-saving RNA medicines to patients," said Joseph E. Payne, President/CEO of Arcturus Therapeutics, Inc. "We are expanding our work force and hiring key individuals to help us develop premier RNA medicines, such as our lead rare disease drug candidate, LUNAR-101, for treatment of transthyretin-mediated amyloidosis."
"San Diego is a city of innovation. Arcturus Therapeutics is an excellent example of the region's entrepreneurial spirit. Outstanding high-growth biotechnology companies like Arcturus are making us a global leader in technological breakthroughs while also providing high quality jobs for San Diegans here at home," said San Diego Mayor Kevin Faulconer.
Project Announcements
Australia-Based Aquatic Leisure Technologies Group Plans Opp, Alabama, Manufacturing Operations
12/11/2025
Teradyne Plans Wixom, Michigan, Robotics Operations
12/11/2025
Robinson Plans Altoona, Iowa, Manufacturing Operations
12/11/2025
BioTouch Expands Columbus, Georgia, Operations
12/11/2025
Natrion Plans Erie County, New York, Battery Components Operations
12/11/2025
Czech-Based GZ PrintPak Expands Mount Pleasant, Wisconsin, Manufacturing Operations
12/11/2025
Most Read
-
The Workforce Bottleneck in America’s Manufacturing Revival
Q4 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
How Canada Stays Competitive
Q3 2025
-
Investors Seek Shelter in Food-Focused Real Estate
Q3 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025